---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005100"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:56:10.679956+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma presents preclinical data on KROS 101 at AACR-JCA; shows tumor reduction in melanoma models

## Summary
- KROS 101, a GITR agonist, enhanced T cell infiltration and proliferation in mouse melanoma models and human glioblastoma in vitro.
- In a preclinical study, KROS 101 reduced melanoma tumor in human GITR knock-in mouse model vs. the GITR antibody TRX518.
- Data presented at the 13th AACR-JCA Joint Conference from Feb 1-5, 2025 in Maui, Hawaii.
- CEO Dr. John S. Yu and VP R&D Dr. Ramachandran Murali co-presented; potential for melanoma and glioblastoma therapy.

## SEC filing metadata
- accession: 0001493152-25-005100
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315225005100/0001493152-25-005100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315225005100/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005100
- JSON: https://secwatch.observer/filing/0001493152-25-005100.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.